ACTR 087

Drug Profile

ACTR 087

Alternative Names: ACTR-087; CD16V-41BB-CD3ζ; Viral ACTR + rituximab - Unum Therapeutics

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator Unum Therapeutics
  • Class Antineoplastics; Monoclonal antibodies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Aug 2016 Phase-I clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (unspecified route) (NCT02776813)
  • 18 Jul 2016 Unum Therapeutics plans a follow-up, observational clinical trial for B-cell lymphoma (Second-line therapy or greater) in USA (Parenteral) (NCT02840110)
  • 20 Jun 2016 Preclinical trials in Non-Hodgkin's lymphoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top